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Abstract 
Background: Symptoms of depression and anxiety are common in adults with cardiovascular diseases (CVDs) and 
diabetes mellitus (DM). The literature on depression and anxiety in CVDs and DM populations is extensive; however, 
studies examining these relationships over time, directly compared to adults without these conditions, are still lack-
ing. This study aimed to investigate trends in depression and anxiety symptom prevalence over more than 20 years in 
adults with CVDs and DM compared to the general population.
Methods: We used data from the population-based Trøndelag Health Study (HUNT), Norway, including adults 
(≥ 20 years) from three waves; the HUNT2 (1995–97; n = 65,228), HUNT3 (2006–08; n = 50,800) and HUNT4 (2017–19; 
n = 56,042). Depressive and anxiety symptom prevalence was measured independently by the Hospital Anxiety and 
Depressions scale (HADS) in sex-stratified samples. We analyzed associations of these common psychological symp-
toms with CVDs and DM over time using multi-level random-effects models, accounting for repeated measurements 
and individual variation.
Results: Overall, the CVDs groups reported higher levels of depression than those free of CVDs in all waves of the 
study. Further, depressive and anxiety symptom prevalence in adults with and without CVDs and DM declined from 
HUNT2 to HUNT4, whereas women reported more anxiety than men. Positive associations of depression and anxiety 
symptoms with CVDs and DM in HUNT2 declined over time. However, associations of CVDs with depression symp-
toms remained over time in men. Moreover, in women, DM was associated with increased depression symptom risk 
in HUNT2 and HUNT4.
Conclusions: Depression and anxiety symptoms are frequent in adults with CVDs. Further, our time trend analysis 
indicates that anxiety and depression are differentially related to CVDs and DM and sex. This study highlights the 
importance of awareness and management of psychological symptoms in CVDs and DM populations.
Keywords: Cardiovascular diseases, Diabetes mellitus, Depression symptoms, Anxiety symptoms, Prevalence, Multi-
level models
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Introduction
Cardiovascular diseases (CVDs) and diabetes melli-
tus (DM) represent major public health challenges, and 
their prevalence rates are steadily rising globally. World 
Health Organization (WHO) estimate that 17.8 million 
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people die from CVDs each year, representing 31% of all 
global deaths [1]. The global population with DM in 2013 
is estimated at 382 million (ages 20 to 79), the number 
expected to rise to 592 million by 2035 [2]. Simultane-
ously, a growing prevalence of depression and anxiety has 
been reported worldwide. In 2017, more than 264 mil-
lion people of all ages worldwide suffered from depres-
sion [3]. The rates varied across studies and countries, 
yet a systematic review from 2016 concluded that the 
anxiety prevalence was generally high (3.8–25%) and par-
ticularly in women (5.2–8.7%) and individuals from Euro-
pean countries (3.8–10.4%) [4]. Higher prevalence rates 
and risk of depression and anxiety in women compared 
to men have been well documented [5, 6]. However, 
whether depression and anxiety prevalence is increasing 
over time is still debated [7, 8].
CVDs and DM populations are often affected by higher 
depression and anxiety symptom load than the general 
population [9, 10]. Research suggests common biological 
pathways of CVDs and DM with depression and anxiety, 
focusing on the autonomic and hypothalamic-pituitary-
adrenal (HPA) axis and immuno-inflammatory dysregu-
lation [11, 12]. Depression and anxiety have different 
clinical manifestations; however, these psychological 
conditions often overlap [13] and appear together with 
CVDs and DM [9, 10], further increasing the burden of 
symptoms in these wide-spread physical illnesses [14].
Worldwide, studies consistently report on increased 
prevalence rates and risk of depression and anxiety in 
adults with CVDs compared to people free from these 
conditions [9, 15–20]. WHO has estimated the preva-
lence of clinical depression in CVDs populations to range 
between 3 and 9% worldwide [9] in the last two decades, 
yet rates between 35 and 46% in China [15] and rates 
as high as 47% have been reported from Iran [18]. A 
recent meta-analysis found that of 10,785 acute myocar-
dial patients, approximately one of five were diagnosed 
with major depression, whereas one of three reported 
mild to moderate symptoms of depression [19]. A study 
using data on population-based adults from 17 countries 
demonstrated a higher odds ratio (OR) for depression 
(adjusted OR 2.1; 95% CI 1.9–2.5) and anxiety (adjusted 
OR 1.4; 95% CI 1.0–1.9) in participants with CVDs 
than those with no such conditions [9]. Likewise, symp-
toms of depression and anxiety are frequently present 
in adults with DM [21–23]. Epidemiological evidence 
suggests that the prevalence of depression is more than 
three times higher in adults with type 1 DM and almost 
twice as high in adults with type 2 DM [21]. In line with 
this, a meta-analysis of longitudinal studies showed that 
people with DM had an average of 30% higher risk of 
developing depression than those without [24]. A recent 
systematic review shows that anxiety disorders and 
anxiety symptoms are present in 14% and 40% of patients 
with DM [22]. These findings correspond to a system-
atic review that reported positive associations between 
DM and both anxiety disorders (pooled OR 1.20; 95% CI 
1.10–1.30) and elevated anxiety symptom levels (pooled 
OR 1.48; 95% CI 1.02–1.93) [25].
Unfortunately, depression and anxiety symptoms often 
go undetected and untreated in CVDs and DM popula-
tions [26, 27]. In turn, this may contribute to poor treat-
ment outcome of the primary disease [28, 29], reduced 
quality of life [30, 31] and increased health care costs 
[32, 33]. Recently, there has, therefore, been a growing 
interest in CVDs and DM populations’ psychological 
conditions and how to improve the clinical practice of 
detection and treatment [34, 35]. Despite the increasing 
literature on depression and anxiety in adults with CVDs 
and DM, studies examining secular trends in depression 
and anxiety symptom levels are lacking. Thus, this study 
aims to investigate the development of depression and 
anxiety symptom levels in CVDs and DM groups, using 
population-based data from three waves of the Trønde-
lag Health Study (HUNT) over more than two decades 
(HUNT2, HUNT3, and HUNT4). The objectives of this 
study are: (1) to describe depression and anxiety symp-
tom load in the populations according to CVDs and DM 
status (2) to investigate time trends of these psychologi-
cal symptoms over 22-years, and to (3) examine the asso-




The HUNT Study is a repeated, serial-entry health 
study of an entire population residing in Nord-Trøn-
delag county (recently included in the larger Trøndelag 
County), Norway, carried out in four waves: HUNT1 
(1984–86), HUNT2 (1995–97), HUNT3 (2006–08), 
and HUNT4 (2017–19). The serial-entry participa-
tion means that all county inhabitants eligible to par-
ticipate (aged 19  years and more) were invited every 
10  years—regardless of whether they had participated 
before or not. This study used data from the HUNT2, 
HUNT3 and HUNT4 waves, where all county adults 
(aged ≥ 20 years) received questionnaires (Q1) to fill out 
before the clinical screening test. A second questionnaire 
(Q2) was distributed to be filled out and returned by mail 
after clinical examination. Of all invited, the number of 
respondents whose data material was available to this 
study was 65,228 (69.5%) in HUNT2, 50,800 (54.1%) in 
HUNT3, and 56,042 (54%) in HUNT4. The number of 
participants and the respective participation rates (in %) 
is per point of data collection, as the number of eligible 
adults in the county changed over time. Information on 
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the participation of cohorts over time is available on the 
HUNT official website [36]. The population in HUNT is 
considered representative of general Norwegian adults 
[37]. All HUNT participants gave their written con-
sent for research on their data. This study was approved 
by the Regional Committees for Medical Research and 
Health Research Ethics in Norway (reference2019/30292/
REK Nord) and the Norwegian Centre for Research Data 
(reference 30292/NSD).
Data material
This study used data from the main questionnaires (Q1 
and Q2) covering a wide range of variables on health 
condition, lifestyle, sociodemographic characteristics, 
and clinical measurements. The participants yielding 
valid data on self-reported depression and anxiety ques-
tions (outcome) and CVDs and/or DM status (exposure) 
were eligible, while those with missing values on both 
exposures were excluded. The study population was ana-
lyzed by diseases status (CVDs and DM) independently 
in sex-stratified samples. Analysis by CVDs status was 
carried out in 61,284 participants from HUNT2, 40,508 
participants from HUNT3 and 40,443 participants from 
HUNT4, including individuals with and without CVDs. 
Samples analyzed by DM status were 61,229 participants 
from HUNT2, 40,504 participants from HUNT3 and 
41,371 participants from HUNT4, including individu-
als with and without DM. Samples of individuals with 
both CVDs and DM were too small (i.e., 204, 164 and 
182 among women and 262, 283 and 385 among men in 
HUNT2, HUNT3 and HUNT4, respectively) to provide 
the necessary statistical power and were therefore not 
analyzed as a separate group. Figure  1 shows the flow 
chart of the study participants selected for this study.
Measurements
Outcome variables: Anxiety and Depression symptoms
The Hospital Anxiety and Depression Scale (HADS) 
was used to assess symptoms of depression and anxiety. 
The HADS is a brief self-report questionnaire consisting 
of 14 items, seven for anxiety subscale (HADS-A) and 
seven for depression subscale (HADS-D), each scored 
on a Likert-scale from 0 (no symptoms) to 3 (symptoms 
maximally present) [38]. For this study, valid ratings of 
the HADS-D and HADS-A were defined as at least five 
completed items on both subscales. The score of those 
who filled in five or six items was based on the sum of 
completed items multiplied by 7/5 or 7/6, respectively. 
We assessed anxiety and depression with the categorical 
approach, using a conventional cut-off threshold of 8 on 
both the HADS subscales. This cut off value is found to 
provide optimal sensitivity and specificity (about 0.80) 
and a good correlation with the case of clinical depression 
based on DSM-III and ICD-8/9 diagnostic criteria [39]. 
Additionally, these conventional cut-offs are often used 
for decision-making purposes, such as rating the sever-
ity of depression or the need for treatment [40]. Reliabil-
ity was examined by ordinal and traditional Cronbach’s 
alpha and performed well on both HADS-A and HADS-
D subscales (ordinal alpha was 0.92 and 0.88; Cronbach’s 
alpha was 0.87 and 0.81, respectively) [41]. The HADS-
subscales has been confirmed as reliable for detecting 
symptoms of anxiety and depression independently and 
describing symptom severity among the CVDs and DM 
populations [42, 43].
Exposure variables
CVDs status was measured with questions on the history 
of heart diseases (myocardial infarct or angina) or stroke 
(yes/no). Question on heart failure was excluded from 
HUNT2, and thus, this condition was not used in the def-
inition of CVDs in this study. History of diabetes, includ-
ing type 1 DM, type 2 DM and other DM types, were 
criteria for defining DM (yes/no). Missing data on CVDs 
and DM were defined as an absence of the diseases.
Other independent variables
Sociodemographic characteristics of the study sample 
included: sex (classified as women and men), age (mean 
and age groups < 55, 55–64 and ≥ 65 years) and cohabi-
tation status (living with someone vs living alone). The 
HUNT3 database lacks direct data describing socioeco-
nomic status (e.g., education level). Therefore, we used 
the lifestyle variable "current smoking" (yes/no) as an 
indicator of socioeconomic status in multivariate analy-
sis. Other lifestyle measurements included monthly alco-
hol consumption (no or low drinking versus moderate to 
frequent) and physical activity (inactive versus active). 
Alcohol consumption in HUNT2 was described numeri-
cally (i.e., times drinking per month) whereas in HUNT3 
and HUNT4 with categories. In this study, never or 
≤ one time per week was defined as no or low drinking, 
while drinking two-three times or ≥ four times per week 
was moderate to frequent drinking. In HUNT, leisure-
time physical activity was measured by questions about 
light (i.e., no sweating or heavy breathing) and hard (i.e., 
sweating, and heavy breathing) physical activity per week. 
We defined the respondents with no physical activity or 
less than one time per week as not physically active, while 
those with more than one time per week of hard/let phys-
ical activity were physically active. Of clinical anthropo-
metric measurements, we used Body mass index (BMI) 
as a general indicator of overweight and obesity, which 
are significant risk factors for cardio-metabolic diseases 
[44], depression [45] and anxiety [46]. Body mass index 
(BMI) included two categories: underweight to normal 
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(<  25  kg/m2) and overweight to obese (≥  25  kg/m2), 
defined according to WHO BMI cut-off for overweight 
and obesity classification [47].
Statistical analysis
The prevalence of self-reported anxiety and depres-
sion symptoms was evaluated using cross-sectional 
data from three HUNT surveys performed with an 
11-years’ interval. Descriptive statistics regarding base-
line characteristics included frequencies and percent-
ages. The study population’s characteristics stratified by 
sex are presented for the sample with a report on CVDs 
(Table 1) and DM status (Table 2) separately. The groups 
with positive disease status in Tables 1 and 2 are bolded. 
Prevalence of depression and anxiety was described sepa-
rately by disease status and across sexes. Estimates were 
age-standardized (using the age categories <  55, 55–64 
and ≥  65  years) by the direct standardization using the 
age distribution of participants attending the screening 
in HUNT3 as the standard population. The associations 
of self-reported depression and anxiety with CVDs and 
DM were analyzed using multi-level logistic models. 
Multi-level models were specified to account for repeated 
measurements on the same participants (i.e., non-inde-
pendent observations). To derive risk ratios (RR) and risk 
differences (RD), we used predictions from the multi-
level models. Specifically, the RR was formed as the ratio 
between the mean predicted probability, whereas RD 
was the difference in mean predicted probability. We 
calculated RR and RD for three specific ages, 40, 60 and 
80. We present findings for age 60 in the results section 
and age 40 and 80 in the supplementary information 
Fig. 1 Flow chart showing the selection  criteriaa for participants. aHospital Anxiety and Depression Scale (HADS) questionnaires, cardiovascular 
diseases (CVDs) and diabetes mellitus (DM) Status. CVDs status defined as CVDs or no-CVDs; DM status was defined as DM or no-DM
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(see Additional files 1 and 2 for CVDs and DM analysis, 
respectively). Associations of diseases status (i.e., CVDs 
and DM) and self-reported depression and anxiety are 
reported with 95 per cent confidence intervals (95% CI). 
All statistical models were sex-stratified. The models 
considered first age adjustment (age and age squared), 
followed by the inclusion of other sociodemographic var-
iables (i.e., smoking and cohabitation) and finally, lifestyle 
measurements (i.e., alcohol consumption, physical activ-
ity and BMI). First we adjusted for BMI using categorical 
approach with cut-off at 25 kg/m2. Second, we used BMI 
as a continuous variable with restricted cubic splines 
and tested for possible non-linear associations between 
the continuous change of BMI and the outcome (anxiety 
and depression symptoms) at four prespecified locations 
according to percentiles of BMI distribution (i.e., 5th, 
25th, 75th and 95th) that correspond to different BMI 
values (i.e., 20.7 kg/m2, 24.1 kg/m2, 26.3 kg/m2, 28.9 kg/
m2, and 34.9  kg/m2, respectively).Statistically significant 
associations of self-reported depression and anxiety with 
CVDs (Table 3) and DM (Table 4) are highlighted in bold. 




Table  1 shows the HUNT2, HUNT3 and HUNT4 
study participants’ characteristics within sex-stratified 
samples according to CVDs status. Overall, the preva-
lence of CVDs was relatively stable from HUNT2 to 
HUNT4 (range from 7.3 to 8.7%) and higher in women 
than men. CVDs groups consistently reported higher 
rates of depression than the no-CVDs group across age, 
sexes and study waves, yet for anxiety, this pattern was 
only observed in women and limited to the first two 
waves of the study. In contrast, DM prevalence consist-
ently increased from HUNT2 to HUNT4 (range from 
2.8 to 6.2%), with rates slightly higher in men than 
women, whereas differences in depression and anxiety 
symptom load between DM and no-DM groups were 
less prominent (Table 2). Participants reporting disease 
(i.e., CVDs or DM) were often 65 years and older, non-
smokers, physically active, reported no to low monthly 
alcohol consumption and were more often overweight 
or obese.
Figure  2 shows the age-standardized anxiety and 
depression symptom prevalence of participants with 
CVDs compared to the no-CVDs group for the study 
period 1995–2019. Within CVDs groups, the symptom 
of depression decreased consistently in women whereas 
initially declined and subsequently increased in men, the 
trends resulting in an overall decrease in both sexes over 
the total study period (from HUNT2 to HUNT4). On 
the other hand, the trend in depressive symptom preva-
lence in groups with no CVDs was stable. Anxiety symp-
tom prevalence declined in the first (1995–2008) and 
Fig. 2 Trends in depression and anxiety symptom  prevalencea according to cardiovascular diseases (CVDs) status, the HUNT 1995–2019. 
aAge-standardized using the age distribution of participants attending a screening in HUNT3 as the standard population. HUNT, The Trøndelag 
Health Study
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increased in the last study period (2008–2019) across all 
study groups and sexes, resulting in an overall decrease 
in participants with CVDs and relative stability in groups 
without this condition. Women reported higher anxiety 
scores than men, a trend observed across all study groups 
and periods.
Similarly, Fig.  3 shows the age-standardized preva-
lence of symptoms of anxiety and depression in partici-
pants according to DM status. Within DM groups of both 
sexes, depressive symptom prevalence showed an overall 
decline in the first period yet increased slightly in women 
and remained largely unchanged in men throughout the 
study period. Such trend resulted in an overall depres-
sive symptom decrease in men with DM and rela-
tive symptom stability in women with this condition. 
From HUNT2 to HUNT3, anxiety symptom prevalence 
declined across all study groups and sexes and subse-
quently increased again in HUNT4, so that anxiety prev-
alence rates in DM groups remained largely unchanged 
in women and declined in men. As in CVDs analyses, 
depression symptom prevalence remained relatively sta-
ble in no-DM participants of both sexes, whereas anxiety 
symptoms increased in the first and declined in the last 
period.
Associations of cardiovascular diseases and diabetes 
with depression and anxiety symptoms at age 60
Table  3 shows associations of CVDs with symptoms 
of depression and anxiety at age 60  years for men and 
women in HUNT2, HUNT3 and HUNT4. Overall, the 
risk differences between individuals with and without 
CVDs declined over time for both sexes yet remained 
statistically significant in men. Among women, RD 
for depression decreased from 0.08 (95% CI 0.07–0.1) 
in HUNT2 to 0.05 (95% CI 0.04–0.07) in HUNT3. In 
HUNT4, there was no statistical evidence for any differ-
ence between those with and without CVDs on either 
depression or anxiety symptoms among women. Men 
with CVDs in HUNT4 had a 26% higher risk for symp-
toms of depression than males with no CVDs, with an 
absolute RD of 0.03 (95% CI 0.01–0.04). In contrast, there 
was no statistical evidence for any difference between 
CVDs groups and anxiety symptoms among men in 
HUNT4.
Table  4 shows that among adults at the age of 60 
with DM in HUNT2, the risk for depression and anxi-
ety symptoms above cut-off levels was raised by 36% 
compared to no-DM groups as a reference, with an RD 
of 0.04 (95% CI 0.02–0.07). There was no difference 
between DM and anxiety or depression risks in either 
sex in HUNT3, whereas 11  years later (HUNT4), DM 
was associated with a 24% increased risk for depres-
sion and 13% increased risk for anxiety in women but 
not in men. Further adjustment for sociodemographic 
and lifestyle variables yielded minimal changes in risk 
estimates in both CVDs and DM analysis (Tables 3, 4), 
and thus, these variables were not included in the final 
model.
Fig. 3 Trends in depression and anxiety symptom  prevalencea according to diabetes mellitus (DM) status, the HUNT 1995–2019. aAge-standardized 
using the age distribution of participants attending a screening in HUNT3 as the standard population. HUNT, The Trøndelag Health Study
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Discussion
Findings from three waves (1995–2019) of this pop-
ulation-based study of more than 140,000 adults 
showed higher depression and anxiety symptom prev-
alence in groups with CVDs and DM than no-disease 
groups, and differences were generally more pro-
nounced in CVDs than DM. Overall, there was a gen-
eral decline in depression symptom prevalence in the 
same period for all study groups. Anxiety symptom 
prevalence decreased initially and increased in the last 
decade across study groups and sexes; still, there was 
an overall symptom reduction in participants with and 
without CVDs or DM. These trends are not in keep-
ing with a meta-analysis that suggested no change in 
the global prevalence of depression and anxiety in the 
general populations in 21 world regions between 1990 
and 2010 [7]. Nevertheless, our results partially reflect 
patterns of depression and anxiety prevalence in other 
Scandinavian countries [48–50] and confirm existing 
evidence of the higher prevalence of depressive and 
anxiety symptoms in populations with CVDs or DM 
than in the general adults [9, 10].
Prevalence of depression and anxiety symptoms according 
to cardiovascular disease and diabetes status
Depression and anxiety symptoms and disorders often 
overlap with CVDs and DM [17, 24, 25, 51] and are more 
frequent in people with these wide-spread physical con-
ditions than in the general population [9, 10]. Largely in 
line with our findings, worldwide population-based sur-
vey data from 17 countries, showed that the prevalence 
of clinically diagnosed depression and anxiety is generally 
higher in CVDs and DM populations than those with no 
such conditions, consistently across countries, sexes, and 
Table 3 Associations of CVDs with depression and anxiety symptoms in HUNT2 (1995–97), HUNT3 (2006–08) and HUNT4 (2017–19), 
multi-level logistic analysis
Adjusted for age and age squared. Risk Ratio (RR) and Risk Difference (RD) between individuals reporting CVDs and no-CVDs (ref.) at age 60
CVDs, Cardiovascular diseases; HUNT, The Trøndelag Health Study; RR, Risk ratio; RD, Risk difference; CI, Confidence Interval
HUNT2 (1995–97) HUNT3 (2006–08) HUNT4 (2017–19) HUNT2 (1995–97) HUNT3 (2006–08) HUNT4 (2017–19)




1.72 (1.55–1.88) 1.57 (1.37–1.76) 1.10 (0.94–1.26) 0.08 (0.07–0.10) 0.05 (0.04–0.07) 0.01 (− 0.01 to 0.03)
 Men
n = 39,012




1.39 (1.28–1.49) 1.28 (1.15–1.40) 1.03 (0.93–1.14) 0.09 (0.07–0.11) 0.05 (0.03–0.07) 0.01 (− 0.01 to 0.03)
 Men
n = 38,754
1.37 (1.25–1.48) 1.28 (1.12–1.43) 1.07 (0.95–1.19) 0.06 (0.04–0.08) 0.03 (0.01–0.04) 0.01 (− 0.01 to 0.03)
Table 4 Associations of DM with depression and anxiety symptoms in HUNT2 (1995–97), HUNT3 (2006–08) and HUNT4 (2017–19), 
multi-level logistic analysis
Adjusted for age and age squared. risk ratio (RR) and risk difference (RD) between individuals reporting DM and no-DM (ref.) at age 60
DM, diabetes mellitus; HUNT, The Trøndelag Health Study; RR, risk difference; RD, risk ratio; CI, confidence interval
HUNT2 (1995–97) HUNT3 (2006–08) HUNT4 (2017–19) HUNT2 (1995–97) HUNT3 (2006–08) HUNT4 (2017–19)




1.36 (1.17–1.56) 1.18 (0.98–1.38) 1.24 (1.06–1.42) 0.04 (0.02–0.07) 0.02 (− 0.00 to 0.04) 0.02 (0.01 to 0.04)
 Men
n = 39,095




1.12 (1.00–1.25) 1.05 (0.91–1.19) 1.13 (1.02–1.24) 0.03(− 0.00 to 0.06) 0.01 (− 0.02 to 0.03) 0.03 (0.01–0.05)
 Men
n = 38,838
1.21 (1.04–1.38) 1.13 (0.93–1.33) 1.12 (0.97–1.26) 0.03 (0.01–0.06) 0.01 (− 0.01 to 0.03) 0.02 (− 0.00 to 0.04)
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age [9, 10]. However, although not directly comparable, 
the depressive symptom prevalence in CVDs groups for 
the period 2006–08 (HUNT3) in our data was closer to 
the prevalence reported for the corresponding period in 
the recent US studies—ranging from 15.8 to 18.3% [52, 
53], than the pooled depressive symptom prevalence in 
community-dwelling adults with CVDs in China and 
Iran ranging from 35 to 47% [15, 18]. Thus, our findings 
broadly agree with the evidence on the prevalence of 
depression (i.e., self-reported or clinically diagnosed) in 
the people with CVDs and the general public to be lower 
in Western countries than in non-Western world region 
[54, 55].
Secular trends in the prevalence of depression and anxiety 
symptoms
Although it is well established that depression and anxi-
ety prevalence is generally higher in people with chronic 
medical conditions than those without, findings on time 
changes in depression and anxiety symptom prevalence 
in the general population and groups with CVDs or DM 
have been inconsistent. Epidemiological studies from 
the last two decades have observed an overall increase in 
depression and anxiety prevalence in the general popula-
tion [48, 56, 57] and CVDs and DM populations [10, 57, 
58]. In contrast, other studies report that these mental 
conditions are on the rise in general adult populations [7, 
59, 60] and populations with CVDs and DM [23, 53, 61].
In contrast to our findings, studies from the USA 
showed that depressive symptom prevalence increased 
in the general population from 2005 to 2016 [57], while 
no change was found in community-dwelling adults with 
heart disease (aged 20–80 years) in the same period [53]. 
Moreover, our prevalence rates of non-disease groups 
align with the literature review and meta-analysis of 
studies on the global prevalence of depression and anxi-
ety symptoms, revealing relative stable rates from 1990 
through 2005 to 2010 [7]. However, the overall decline 
of depression symptoms across CVDs/DM groups in this 
study corresponds to a general reduction in the pooled 
global prevalence of depression symptoms and disor-
ders observed in various outpatient groups from 1995 
to 2010, from 83 cross-sectional studies mainly from 
Europe, Asia and North America [54]. This change was 
partly explained by improved treatment and awareness of 
these psychological conditions [54]. Similarly, the decline 
in depressive symptom rates was observed in a popula-
tion-based sample of Mexican adults with DM (aged 
≥ 50 years) from 2001 to 2015 [23].
A decrease in anxiety symptom prevalence from 1995 
to 2008 in our data is not in keeping with a meta-analy-
sis that relied on data from 44 countries and concluded 
no change in the global prevalence of anxiety in adults 
(clinically diagnosed or self-reported) for the period 
1990–2010 [8]. On the other hand, Swedish findings from 
1980 to 2005 showed a general increase in self-reported 
anxiety rates among adults aged 16–63 years [48]. Nev-
ertheless, the same study also observed a decline in 
anxiety symptom prevalence in the oldest female groups 
(aged 64–71  years), in line with trends observed in our 
data. Similarly, another population-based Swedish study 
that examined time trends in self-reported anxiety from 
1997 to 2006 reported an increase in participants aged 
≤ 24 years, whereas a decrease or stable estimates in the 
other adult groups (25  years and more) from 2001 and 
onwards [49]. A study of national representative Dutch 
adults (aged 18–64  years) observed no change in the 
prevalence of clinically diagnosed anxiety and depression 
from 1995 to 2009 [50].
Variations in instruments and criteria, sampling, study 
location/country, and characteristics of underlying popu-
lations make it difficult to directly compare and interpret 
study findings [62, 63]. In sum, changes in depression and 
anxiety symptom prevalence for the period 1995–2019 
(HUNT2 to HUNT4) within a national representative 
sample of Norwegian adults are in keeping with com-
parable studies reporting on depression and anxiety 
symptom trends in the same age groups in other Scan-
dinavian countries [48, 50]. Moreover, anxiety symp-
tom rates for the period 2006–19 (HUNT3 to HUNT4) 
showed a marked increase across all study groups and in 
both sexes. The increase in anxiety symptoms has been 
linked to the global rise in psychological stressors such as 
work-life stress [64], urbanization [65] and social media 
use [66] observed in past decades. However, understand-
ing the extent to which our findings on increasing anxiety 
prevalence reflect the growing trend in stress-related risk 
factors for anxiety, particularly within specific subgroups, 
requires further investigation. On the other hand, the 
overall reduction in symptoms of depression and anxi-
ety in our study over two decades may, in addition to 
the above-mentioned cohort effect, to some degree be 
a result of altered lifestyle behaviour (i.e., non-smoking, 
physical activity and no-low alcohol use) of study par-
ticipants becoming "healthier" from HUNT2 to HUNT3, 
particularly in those with a diagnosis of CVDs and DM, 
which in turn could have contributed to improved mental 
health outcomes [67–69]. However, the overall decrease 
or relative stability of mental health symptoms in our 
data may reflect an overall improved public recognition 
of common mental conditions, particularly in groups 
with wide-spread physical conditions or increased aware-
ness of people with such diseases to seek mental health 
help [60, 70].
Importantly, the diagnostic criteria for several physi-
cal illnesses have changed around the time of HUNT2 
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[71]. These changes lowered the thresholds for CVDs 
and DM diagnosis, contributing to higher prevalence and 
a "healthier" population with these conditions [72, 73]. 
This change might, at least partly, contribute to the gen-
eral decline of the existing depression symptom burden 
across the three HUNT surveys and the drop in anxiety 
symptoms from HUNT 2 to HUNT3. Nevertheless, these 
changes have most likely affected CVDs and DM popu-
lations similarly in most of the world—both in terms of 
physical and mental symptom burden.
Higher prevalence, severity, and burden of anxiety 
and depression have consistently been documented in 
women compared to men in general, CVDs and DM pop-
ulations [5, 6, 21, 22, 52]. Our study confirmed existing 
evidence that anxiety symptoms were more common in 
women than in men, irrespectively of CVDs or DM sta-
tus. In contrast, the analysis of our data generally yielded 
marginal sex-differences in depressive symptom preva-
lence, except in the CVDs population in HUNT4, where 
men reported more depression than women. This can 
largely be attributed to the psychometric properties of 
the HADS-D subscale, also confirmed in a previous study 
of the HUNT2 cohort [74].
Associations of anxiety and depression symptoms 
with cardiovascular diseases and diabetes
In our study, CVDs or DM was positively associated 
with depression and anxiety symptom risk in HUNT2 
(1995–97). However, over 22  years, these associations 
declined, except for CVDs and symptoms of depres-
sion in men that remained across studies. Moreover, in 
women, DM was associated with an increased risk of psy-
chological symptoms, greater for depression than anxiety 
in HUNT2 and HUNT4.
The findings that CVDs are significantly associated 
with symptoms of depression and anxiety are consistent 
with literature showing that these psychological symp-
toms are common after CVDs [16, 20, 75]. A literature 
review and meta-analysis of studies examining several 
vascular risk factors of late-life depression (clinically 
diagnosed or self-reported) found positive associations 
of CVDs with depression (pooled OR 1.76; 95% CI 1.52–
2.04) [68]. Similarly, a meta-analysis reporting on post-
stroke anxiety found self-reported anxiety in one of five 
stroke survivors [16]. The strength and significance of the 
associations of CVDs with depression and anxiety symp-
toms in our data changed over time across sexes, the 
results inconsistent compared to previous research. How-
ever, research has addressed that psychological reactions 
following CVDs events differ in women and men. Results 
from a meta-analysis of studies examining depression 
after CVDs diagnosis/events across sexes suggested that 
women experience a higher level of depression initially 
after a coronary heart event than men. However, in most 
women, symptoms tend toward improving over time, 
whereas men typically reported more long-lasting dis-
tress and depressive symptom burden [76].
It has been documented that several psychological 
conditions related to diabetes, such as stress followed by 
the diagnosis, feeling of the burden caused by demand-
ing lifestyle and self-care behavior, fear of hypoglycemia, 
diabetes complication, and invasive procedures, may 
impose depression and anxiety [77]. Moreover, a meta-
analysis showed that DM is associated with, on average, 
a 30% increased risk for both self-reported and clinically 
diagnosed depression [24], which partly correspond to 
our findings. However, these associations remained sta-
tistically significant only in women in two study waves 
about 20 years apart. These findings agree with a litera-
ture review on diabetes stress, an emotional state char-
acteristical for type 2DM, that reported diabetes stress is 
more frequent in women than men and often followed by 
depression [78].
Strengths and limitations
This study has several strengths. First, it used an inter-
nationally renowned health database to examine changes 
in depression and anxiety symptoms over more than 
20 years in people with CVDs, DM, and adults residing in 
the same area without these diseases. Second, the study 
sample is relatively large and comprises an adult popula-
tion representative of the general Norwegian adult popu-
lation. Of note, HADS was specifically designed to detect 
anxiety and depression in patients with cardiovascular/
physical conditions. Therefore, it covers core psychologi-
cal symptoms of depression and anxiety, yet excludes all 
physical conditions (i.e., dizziness, fatigue, insomnia, and 
others) frequently present in both mental and physical 
disorders to avoid misclassification and reverse causality 
[13, 79].
This study also has some limitations. Depression and 
anxiety symptoms were based on self-rating rather than 
clinical interviews. This makes direct comparison with 
studies of diagnostic categories of anxiety and depression 
difficult. However, it is quite time consuming to perform 
diagnostic interviews, and this method is hardly feasible 
in large scale studies such as HUNT. In addition, using 
self-reported instruments with cut-off values to meas-
ure anxiety and depression levels might represent a pos-
sible source of bias, and using continuous scores could 
have utilized the available information along the whole 
range of the HADS scale. Thus, the definitive diagnosis of 
depression must be based on the results from the clinical 
interviews and the assessment of functional and somatic 
symptoms. However, the HADS instrument has been 
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used in various settings, and cut-off levels have been well 
defined in the literature [39].
Furthermore, decreasing participation rates from 
HUNT2 to HUNT3 (i.e., on average, by 15.4%) may also 
have influenced the results. However, it should be noted 
that participation rates alone do not necessarily indicate 
selection bias [80]. Further, CVDs and DM were self-
reported, which introduce the possibility that reporting 
bias and misclassification may have affected our results.
Overall, this study’s results can mainly be generalized 
to middle-aged and elderly community-dwelling adults 
[37]. The overall prevalence rates of CVDs, DM, anxiety 
and depression, are likely underestimated as some indi-
viduals were too ill to participate. However, we argue that 
this study provides valid, up-to-date information on time 
trends in anxiety and depression symptoms in a nation-
ally representative sample of adults over 22 years, across 
CVDs and DM status and age.
Conclusion
We observed a declining trend in symptoms of depres-
sion and anxiety for the last two decades, irrespectively of 
age, sex, and CVDs or DM status. Women reported con-
sistently more anxiety than men, whereas associations of 
CVDs with depression symptom remained over time in 
men. However, our findings indicate that depression and 
anxiety symptom load is still higher in people with CVDs 
or DM than in the general public. Anxiety and particu-
larly depression are negatively associated with help-seek-
ing, adherence to treatment and outcomes of CVDs and 
DM. Therefore, more attention to those with coexisting 
mental health problems during the treatment of these 
physical diseases should be warranted. Further research 
should focus on how the treatment of depression and 
anxiety might improve CVDs and DM outcomes, and 
vice versa.
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